Efficacy and safety of dutasteride compared with finasteride in treating males with benign prostatic hyperplasia: A meta‑analysis of randomized controlled trials

Abstract

The present study was an updated meta-analysis that aimed to confirm the efficacy and safety of dutasteride (0.5 mg) and finasteride (5 mg) in treating males with benign prostatic hyperplasia (BPH) over a treatment period of at least 6 months. Randomized controlled trials were retrieved using the MEDLINE, EMBASE and the Cochrane controlled trials register databases. The references of the associated articles were also searched. A systematic review was performed by using the preferred reporting items for systematic reviews and meta-analyses. The data were analyzed with RevMan v5.3.0. A total of six articles including 2,041 participants were studied. The analysis demonstrated a significantly greater decrease in international prostate symptom score [IPSS; mean difference (MD),-0.86; 95% CI,-1.62 to-0.11; P= 0.02] and prostate-specific antigen (PSA; MD,-0.13; 95% CI,-0.26 to-0.01; P= 0.03) in the dutasteride group compared with that in the finasteride group, whereas no significant differences were observed in prostate volume (PV; P= 0.64), maximum urine flow rate (Qmax; P=0.29) and post-void residual volume (PVRV; P=0.14). With regard to safety assessment, including any adverse event (P= 0.66), decreased libido (P= 0.39) and impotence (P= 0.17), there was no significant difference between dutasteride and finasteride. In conclusion, in patients with BPH, dutasteride produced a greater decrease in IPSS and PSA compared with finasteride, whereas no significant differences were identified in PV, Qmax and PVRV. The two drugs appeared to have similar rates of adverse effects, particularly with regard to sexual dysfunction.

Efficacy and safety of Lianhua Qingwen granule in the treatment of non-influenza viral pneumonia: a randomized, double-blind, placebo-controlled, multicenter clinical study

“…The exclusion criteria were as follows: (1) Without definitive evidence of bacterial infection (PCT > 1ug/L); (2) patients receiving other antiviral drugs within 1 week; (3) Patients who met the diagnosis criteria of severe pneumonia in accordance with the 2015 Chinese Guidelines for Diagnosis and Treatment of Communityacquired Pneumonia; (4) Chest CT confirmed severe interstitial lung disease, bronchiectasis, and other underlying lung diseases; (5) Patients with positive influenza A/B rapid test results and with streptococcus pneumonia, Legionella pneumonia urine antigen, mycoplasma pneumonia, and positive chlamydia antibody testing; (6) Patients with severe liver and kidney dysfunction: ALT /AST values were 3 times higher than the upper limit of normal value, and blood creatinine was 1.5 times higher than the upper limit of normal value; (7) Patients with previous or current diseases that might affect their participation in the trial and the research results, including malignant, autoimmune, liver and kidney, hematological, neurological endocrine diseases; (8) Patients with diseases such as human immunodeficiency virus infection, hematological disorders, or received treatments such as splenectomy and organ transplantation, which seriously affected their immune system; (9) History of seizures, mental illness, drinking alcohol, and illicit drug abuse; (10) Pregnant or lactating women.…”

Clinical and economic analysis of different surgical approaches for benign prostatic hyperplasia (literature review)

“…Действительно, активное применение препаратов из группы стероидных ингибиторов 5α-редуктазы (дутастерид, финастерид), α 1 -адреноблокаторов (тамсулозин) и их комбинаций позволяет контролировать прогрессирование обструкции мочевыводящих путей при ДГПЖ и тем самым снизить расходы на ведение пациентов в краткосрочной перспективе [9]. Однако, принимая во внимание риск развития идиосинкразии, резистентности, толерантности к фармакотерапии, снижения качества жизни в долгосрочной перспективе, урологи продолжают развивать методы оперативного лечения ДГПЖ.…”

The efficacy and safety of dutasteride and finasteride in patients with benign prostatic hyperplasia: a systematic review and meta-analysis

“…Finasteride reduces 70% of circulating DHT levels, while dutasteride almost completely reduces DHT levels in both the serum and the prostate. A study found that in treating BPH, compared with finasteride, dutasteride showed a greater decrease in prostate-specific antigen (PSA) and International Prostate Symptom Score (IPSS) (6). Whereas, results of Yin et al suggested no significant differences between dutasteride and finasteride in treating BPH, except dutasteride improves BPH symptoms in IPSS (7).…”